• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ypsomed unveils new autoinjector

October 17, 2022 By Sean Whooley

Ypsomed YpsoMate 5.5 autoinjector
The YpsoMate 5.5 autoinjector. [Image from Ypsomed]
Ypsomed (SIX:YPSN) announced today that it developed a new autoinjector platform for liquid medications with volumes between 1.5 mL and 5.5 mL.

Burgdorf, Switzerland-based Ypsomed built the YpsoMate 5.5 autoinjector on the established technology of the YpsoMate 2.25 Pro. The latest addition to the YpsoMate portfolio enables self-administration for larger-volume medications. These medications may treat cancer, as well as rare and autoimmune diseases.

Self-medication makes daily life easier for people with chronic diseases and reduces healthcare burdens, Ypsomed said in a news release. The company’s self-injection system with a pre-filled syringe allows patients to treat themselves at home instead of visiting a medical facility. Larger dosing volumes can also reduce the number of injections they require.

“YpsoMate 5.5 represents the newest member of the YpsoMate autoinjector family and expands the application range of current autoinjectors by enabling the administration of larger volumes in the range of 2.0 to 5.5 ml from a pre-filled syringe,” said Ulrike Bauer, chief business officer for delivery systems at Ypsomed. “We are setting a new standard for self-management of chronic diseases.”

The YpsoMate 5.5 autoinjector features a two-step handling process for simplicity and safety. Removing the cap and pushing against the skin triggers the injection process automatically. The device also comes with a handgrip to allow comfortable handling and a stable hand position. It emits a continuous visual and audible signal to offer control over the injection process.

Ypsomed said its autoinjector also features an integrated, pre-filled syringe developed in collaboration with Schott Pharma. The joint development resulted in the syriQ BioPure 5.5 mL, a large-volume, pre-fillable syringe with an integrated needle.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: Ypsomed

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS